Efficacy of ozagrel trometamol combined with alteplase in the treatment of acute cerebral infarction
CHEN Junhui
ZHONG Xin
ZHAO Yucai
Abstract：Objective To explore the efficacy of ozagrel trometamol combined with alteplase in the treatment of acute cerebral infarction(ACI).Methods A total of 84 ACI patients admitted to Yuancheng District People's Hospital of Heyuan City,Guangdong Province from May 2022 to April 2025 were retrospectively analyzed.Based on the different treatment meth-ods,patients receiving basic treatment combined with alteplase were assigned to the control group(n=42),while those receiving basic treatment combined with ozagrel trometamol and alteplase were assigned to the combination group(n=42).Patients in both the reference and combination groups received continuous treatment for two weeks.The clinical efficacy,adverse reactions,and levels of serum lipoprotein-associated phospholipase A2(Lp-PLA2),homocysteine(Hcy),Barthel Index(BI)score,and Nation-al Institutes of Health Stroke Scale(NIHSS)score before and after treatment were compared between the control group and the combination group.Results The effective rate in the combination group(95.24%,40/42)was significantly higher than that in the control group(80.95%,34/42)(χ2=4.086,P=0.043).After treatment,the serum Lp-PLA2 and Hcy levels in the combination group((152.04±17.59)ng/mL,(12.79±2.91)μmol/L)were lower than those in the control group((183.01±19.20)ng/mL,(16.54±3.17)μmol/L),with statistically significant differences(t=7.708,5.648,both P<0.05).After treatment,the NIHSS score of the combi-nation group((9.08±0.95)points)was lower than that of the control group((15.36±1.28)points),with a statistically significant difference(t=25.532,P<0.05),and the BI score of the combination group((67.19±6.86)points)was higher than that of the control group((50.78±5.10)points),with a statistically significant difference(t=12.441,P<0.05).The total incidence of adverse reactions in the control group and the combined group was 14.29%(6/42)and 21.43%(9/42),respectively,and the difference was not sta-tistically significant(χ2=0.730,P=0.393).Conclusion The combination of ozagrel trometamol and alteplase demonstrates favor-able clinical efficacy in the treatment of ACI,effectively reducing serum Lp-PLA2 and Hcy levels,improving patients'activities of daily living,promoting neurological function recovery,and exhibiting a good safety profile.
Keywords：acute cerebral infarctionozagrel trometamolalteplaselipoprotein-associated phospholipase A2homocysteine
Publication Date：2025-11-25
Online Publishing Date：2025-12-04(First online date of this platform, not the publication date of the document)
Pages：5( 1325-1329 )